CSat Investment Advisory L.P. bought a new position in shares of CME Group Inc (NASDAQ:CME) during the second quarter, Holdings Channel reports. The fund bought 13,165 shares of the financial services provider’s stock, valued at approximately $2,158,000. CME Group comprises about 1.1% of CSat Investment Advisory L.P.’s investment portfolio, making the stock its 21st biggest position.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Meeder Asset Management Inc. boosted its stake in shares of CME Group by 84.8% in the 2nd quarter. Meeder Asset Management Inc. now owns 789 shares of the financial services provider’s stock valued at $129,000 after purchasing an additional 362 shares during the last quarter. Kaizen Advisory LLC boosted its stake in shares of CME Group by 151.9% in the 2nd quarter. Kaizen Advisory LLC now owns 816 shares of the financial services provider’s stock valued at $134,000 after purchasing an additional 492 shares during the last quarter. Signaturefd LLC bought a new stake in shares of CME Group in the 1st quarter valued at $138,000. Old Mutual Global Investors UK Ltd. bought a new stake in shares of CME Group in the 1st quarter valued at $138,000. Finally, McKinley Carter Wealth Services Inc. bought a new stake in shares of CME Group in the 1st quarter valued at $142,000. 84.04% of the stock is currently owned by hedge funds and other institutional investors.

CME Group stock opened at $177.05 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.08 and a current ratio of 1.08. CME Group Inc has a 12-month low of $124.51 and a 12-month high of $177.07. The firm has a market cap of $59.32 billion, a P/E ratio of 37.12, a P/E/G ratio of 3.27 and a beta of 0.63.

CME Group (NASDAQ:CME) last released its earnings results on Thursday, July 26th. The financial services provider reported $1.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.72 by $0.02. CME Group had a net margin of 111.45% and a return on equity of 9.03%. The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the previous year, the company earned $1.22 EPS. CME Group’s quarterly revenue was up 14.6% compared to the same quarter last year. equities research analysts expect that CME Group Inc will post 6.68 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 25th. Investors of record on Monday, September 10th will be given a dividend of $0.70 per share. The ex-dividend date is Friday, September 7th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.58%. CME Group’s payout ratio is presently 58.70%.

In other CME Group news, Director Ronald A. Pankau sold 260 shares of the company’s stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $163.17, for a total transaction of $42,424.20. Following the transaction, the director now owns 3,900 shares in the company, valued at $636,363. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Ronald A. Pankau sold 250 shares of the company’s stock in a transaction on Thursday, June 7th. The stock was sold at an average price of $171.51, for a total transaction of $42,877.50. Following the transaction, the director now owns 3,559 shares in the company, valued at approximately $610,404.09. The disclosure for this sale can be found here. Insiders have sold a total of 14,519 shares of company stock worth $2,360,150 in the last quarter. 0.45% of the stock is owned by corporate insiders.

CME has been the topic of a number of analyst reports. BidaskClub raised shares of CME Group from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, June 6th. Zacks Investment Research lowered shares of CME Group from a “hold” rating to a “sell” rating in a research note on Wednesday, August 22nd. Compass Point initiated coverage on shares of CME Group in a research note on Monday, July 9th. They issued a “neutral” rating and a $170.00 price objective on the stock. Wells Fargo & Co upped their price objective on shares of CME Group from $170.00 to $175.00 and gave the company a “market perform” rating in a research note on Monday, July 9th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $190.00 price objective on shares of CME Group in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the company. CME Group has a consensus rating of “Buy” and a consensus price target of $171.60.

About CME Group

CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals.

Recommended Story: Short Selling

Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc (NASDAQ:CME).

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.